Objective: A relatively new class of anticancer agents known as proteasome inhibitors is available for treatment of certain human malignancies. This study will determine whether proteasome inhibition will reverse E6-mediated p53 degradation in vivo and in vitro to predict the feasibility of treatment of human papilloma virus (HPV)–associated head and neck cancer.
Design: Molecular analysis.
Subjects: Primary mouse tonsil epithelium cell lines transduced with a retrovirus containing HPV16 E6 model human HPV-associated head and neck cancer. The E6-expressing mouse tonsil epithelium cell lines are immortal and form tumors when implanted in isogenic, immune-competent animals. Human tonsil epithelial cells are similarly isolated and transduced, followed by treatment and analysis.
Harris GF, Lee JH. S108 Proteasome Inhibition Reverses E6-Mediated p53 Degradation and Decreases Proliferation in Tonsil Epithelial Cells. Arch Otolaryngol Head Neck Surg. 2006;132(8):863. doi:10.1001/archotol.132.8.863-a